Internalizing anti-cd74 antibodies and methods of use
AssigneeImmunomedics, Inc.
InventorsHANS J. HANSEN, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
Claims34
A human, chimeric, or humanized anti-CD74 antibody, wherein said antibody is internalized by Raji lymphoma cells in culture and said antibody induces apoptosis of Raji cells in cell culture when cross-linked with goat antisera reactive with the Fc of a human IgG.
A human, chimeric, or humanized anti-CD74 antibody or fragment thereof, wherein said antibody or fragment thereof has at least one of the following properties:
- a) binds to the same epitope of CD74 as the murine LL1 antibody;
- b is internalized by Raji lymphoma cells in culture;
- and
- c) induces apoptosis of Raji cells in cell culture when cross-linked with goat antisera reactive with the Fc of a human IgG.
Dependencies are inferred from the claim text.